Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Managing Bronchiolitis and Respiratory Syncytial Virus

Managing Bronchiolitis and Respiratory Syncytial Virus EDITORIAL Managing Bronchiolitis and Respiratory Syncytial Virus Finding the Yellow Brick Road N THIS ISSUE OF THE ARCHIVES, THE 2 STUDIES BY lows it to benefit the common clinical expression of 1 2 Bordley et al and King et al clearly point out wheezing, whatever its genesis. the conundrums, confusion, and concerns re- Ribavirin is the only therapeutic agent currently ap- garding the currently available methods of di- proved for RSV infections in hospitalized infants. How- I agnosis and testing as well as pharmacologic ever, new pharmacologic modalities are in development therapies for bronchiolitis in young children. These well- based on advances in deciphering the conundrum of the designed reviews conclude that the present indications immune response to RSV, such as specific chemokine and 11-13 for testing and efficacy of the therapeutic modalities dis- cytokine blockers. Nevertheless, therapeutic agents cussed are insufficient. The results produce 2 major ques- are unlikely to provide a significant long-term effect on tions: Why is no benefit or efficacy demonstrated, and the health care burden from RSV. Morbidity during acute where do we go from here? infection may be diminished, but not the aftermath— The lack of effective approaches to management may the rowen http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Pediatrics American Medical Association

Managing Bronchiolitis and Respiratory Syncytial Virus

Hall, Caroline Breese
JAMA Pediatrics , Volume 158 (2) – Feb 1, 2004
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/managing-bronchiolitis-and-respiratory-syncytial-virus-5Ht1X2Vl2t

References (17)

Publisher
American Medical Association
Copyright
Copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6203
eISSN
2168-6211
DOI
10.1001/archpedi.158.2.111
pmid
14757601
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Managing Bronchiolitis and Respiratory Syncytial Virus Finding the Yellow Brick Road N THIS ISSUE OF THE ARCHIVES, THE 2 STUDIES BY lows it to benefit the common clinical expression of 1 2 Bordley et al and King et al clearly point out wheezing, whatever its genesis. the conundrums, confusion, and concerns re- Ribavirin is the only therapeutic agent currently ap- garding the currently available methods of di- proved for RSV infections in hospitalized infants. How- I agnosis and testing as well as pharmacologic ever, new pharmacologic modalities are in development therapies for bronchiolitis in young children. These well- based on advances in deciphering the conundrum of the designed reviews conclude that the present indications immune response to RSV, such as specific chemokine and 11-13 for testing and efficacy of the therapeutic modalities dis- cytokine blockers. Nevertheless, therapeutic agents cussed are insufficient. The results produce 2 major ques- are unlikely to provide a significant long-term effect on tions: Why is no benefit or efficacy demonstrated, and the health care burden from RSV. Morbidity during acute where do we go from here? infection may be diminished, but not the aftermath— The lack of effective approaches to management may the rowen

Journal

JAMA Pediatrics – American Medical Association

Published: Feb 1, 2004

There are no references for this article.